| Name | Title | Contact Details |
|---|---|---|
Curtis Generous |
Chief Technology Officer | Profile |
Glowforge is a beautiful device that sits on your desk. It uses a laser to carve and engrave products from raw materials like wood, leather, acrylic – even cardboard. If you haven`t already, check out our video on glowforge.com. While you`re there, you`ll notice something amazing: Glowforge is the largest crowdfunding campaign in history. There is an incredible demand for what we`re creating. It`s not a geeky tool for the tech elite or a garage workshop; we`re crafting an iconic product that is going to change the way people think about creativity. Our customers include consumers, digital designers, crafters, engineers, teachers, artists, and more. After wrapping up the biggest 30 day crowdfunding campaign in history, we put together a team of incredible people who we are humbled and excited to call our co-workers. We hail from tech giants like Amazon, Google, and Apple, and top startups like Tableau, Tesla, and Evernote. One thing we have all have in common? We want to build see a future where printing a wallet (or a lamp, or a birthday card, or a stunning sushi wrap) is just as easy as printing a resume.
Kalido is the leading provider of business-driven data governance software.
Typeface is a generative AI application for enterprise content creation that empowers businesses to create exceptional, on-brand content at supercharged speeds.
Janus Health is a company that provides a platform designed to help solve healthcare revenue cycle problems, with a focus on improving efficiency and cash collection.
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.